The author presents her thoughts on policies from U.S. Food and Drug Administration (FDA) commissioner Scott Gottlieb on reducing drug prices and medical care costs. Topics covered include generic drug laws, the effects of competition in the pharmaceutical industry, and FDA drug approval practices.
© 2001-2024 Fundación Dialnet · Todos los derechos reservados